Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:663553rdf:typepubmed:Citationlld:pubmed
pubmed-article:663553lifeskim:mentionsumls-concept:C0020981lld:lifeskim
pubmed-article:663553lifeskim:mentionsumls-concept:C0009498lld:lifeskim
pubmed-article:663553lifeskim:mentionsumls-concept:C1179435lld:lifeskim
pubmed-article:663553lifeskim:mentionsumls-concept:C1704207lld:lifeskim
pubmed-article:663553lifeskim:mentionsumls-concept:C1705248lld:lifeskim
pubmed-article:663553lifeskim:mentionsumls-concept:C1548799lld:lifeskim
pubmed-article:663553lifeskim:mentionsumls-concept:C1524073lld:lifeskim
pubmed-article:663553lifeskim:mentionsumls-concept:C0449432lld:lifeskim
pubmed-article:663553pubmed:issue5lld:pubmed
pubmed-article:663553pubmed:dateCreated1978-8-28lld:pubmed
pubmed-article:663553pubmed:abstractTextA metabolic study with radioactively labelled C3 has been performed in a patient with angioimmunoblastic lymphadenopathy (AILD). The labelled protein was metabolized at a faster rate in the patient than in normal individuals. This indicates that the humoral immune system may be of pathogenetic significance in the AILD syndrome.lld:pubmed
pubmed-article:663553pubmed:languageenglld:pubmed
pubmed-article:663553pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:663553pubmed:citationSubsetIMlld:pubmed
pubmed-article:663553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:663553pubmed:statusMEDLINElld:pubmed
pubmed-article:663553pubmed:monthMaylld:pubmed
pubmed-article:663553pubmed:issn0036-553Xlld:pubmed
pubmed-article:663553pubmed:authorpubmed-author:TeisbergPPlld:pubmed
pubmed-article:663553pubmed:authorpubmed-author:HalvorsenSSlld:pubmed
pubmed-article:663553pubmed:authorpubmed-author:SkjortenFFlld:pubmed
pubmed-article:663553pubmed:authorpubmed-author:AkessonIIlld:pubmed
pubmed-article:663553pubmed:authorpubmed-author:BrinchLLlld:pubmed
pubmed-article:663553pubmed:issnTypePrintlld:pubmed
pubmed-article:663553pubmed:volume20lld:pubmed
pubmed-article:663553pubmed:ownerNLMlld:pubmed
pubmed-article:663553pubmed:authorsCompleteYlld:pubmed
pubmed-article:663553pubmed:pagination394-8lld:pubmed
pubmed-article:663553pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:663553pubmed:meshHeadingpubmed-meshheading:663553-H...lld:pubmed
pubmed-article:663553pubmed:meshHeadingpubmed-meshheading:663553-L...lld:pubmed
pubmed-article:663553pubmed:meshHeadingpubmed-meshheading:663553-L...lld:pubmed
pubmed-article:663553pubmed:meshHeadingpubmed-meshheading:663553-F...lld:pubmed
pubmed-article:663553pubmed:meshHeadingpubmed-meshheading:663553-M...lld:pubmed
pubmed-article:663553pubmed:meshHeadingpubmed-meshheading:663553-C...lld:pubmed
pubmed-article:663553pubmed:year1978lld:pubmed
pubmed-article:663553pubmed:articleTitleHypercatabolism of the third component of complement (C3) in angioimmunoblastic lymphadenopathy.lld:pubmed
pubmed-article:663553pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:663553pubmed:publicationTypeCase Reportslld:pubmed